Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an update.
Shandong Xinhua Pharmaceutical Company Limited announced that its wholly-owned subsidiary, Shandong Zibo Xincat Pharmaceutical Company Limited, has received a Drug Registration Certificate for its Ursodeoxycholic Acid Capsules from the National Medical Products Administration. This approval marks a significant step for the company in expanding its product offerings and strengthening its position in the pharmaceutical market, potentially impacting its operations and stakeholders positively.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited operates in the pharmaceutical industry, focusing on the production and distribution of various pharmaceutical products. The company is known for its development of prescription drugs, with a market focus on both domestic and international markets.
Average Trading Volume: 8,154,323
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.64B
Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.